Edition:
United States

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

91.21USD
15 Dec 2017
Change (% chg)

$6.73 (+7.97%)
Prev Close
$84.48
Open
$91.06
Day's High
$92.07
Day's Low
$90.17
Volume
322,304
Avg. Vol
43,268
52-wk High
$104.09
52-wk Low
$59.67

Chart for

About

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

Dec 15 2017

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)

Dec 11 2017

BRIEF-Galapagos NV ‍announces share capital increase arising from warrant exercises​

* ‍Announces a share capital increase arising from warrant exercises​

Nov 23 2017

BRIEF-Galapagos NV reports Q3 loss of ‍1.75​ euro per share

* Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​

Oct 26 2017

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

Sep 27 2017

BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial

* GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial

Aug 09 2017

BRIEF-Galapagos H1 revenues up at EUR 73.0 mln

* ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO

Jul 28 2017

BRIEF-Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos

* SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S.

Jul 27 2017

BRIEF-Galapagos announces new phase 2 study with filgotinib

* NEW PHASE 2 STUDY WITH FILGOTINIB IN NON-INFECTIOUS UVEITIS‍​

Jul 05 2017

BRIEF-Galapagos announces successful completion of Phase 1

* GALAPAGOS' RESEARCH AND DEVELOPMENT UPDATE 2017: RAPIDLY ADVANCING OUR PRODUCT CANDIDATES

Jun 20 2017

Earnings vs. Estimates